nonnucleoside

RO-0335 is a potent diphenylether nonnucleoside reverse transcriptase inhibitor. RO-0335 inhibits Wt HIV-1 (IC50 = 1.1 nM) and retained activity (IC50< 100 nM) against 92% of a large number of NNRTI-resistant clinical isolates.

Rilpivirine (R278474) is a diarylpyrimidine derivative and reverse transcriptase inhibitor with antiviral activity against HIV-1 that is used in the treatment of HIV infections.

BVDV-IN-1 is a non-nucleoside inhibitor (NNI) of bovine viral diarrhea virus (BVDV) with an EC50 of 1.8 μM, directly binding to a hydrophobic pocket of the BVDV RdRp, and demonstrating antiviral activity against BVDV resistant to NNI thiosemicarbazone (TSC).

Lomibuvir (VCH-222) is a selective, non-nucleoside allosteric inhibitor of HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC 50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo -initiated RNA synthesis [1].

Lersivirine (UK-453061)(UK 453061) is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) under development for HIV infection therapy.

ABT-072 is a nonnucleoside NS5B polymerase inhibitor and a candidate drug evaluated for treatment of hepatitis C virus.

Reverse transcriptase-IN-1 is a diarylbenzopyrimidine (DABP) analogue and a potent inhibitor of HIV-1 nonnucleoside reverse transcriptase with an IC50of 13.7 nM.

MIV-150 is a nonnucleoside inhibitor of reverse transcriptase (NNRT). MIV-150 also blocking HIV-1 and HIV-2 infections (EC50<1 nM against HIV-1/HIV-2MN).

SJ3366 is a unique and highly potent nonnucleoside reverse transcriptase human immunodeficiency virus type 1 and HIV-2 inhibitor.

Efavirenz, (R)- is an antiviral agent and a nonnucleoside HIV-1 reverse transcriptase inhibitor.

A 75925, a nonnucleoside reverse transcriptase inhibitors (NNRTI), works to inhibit HIV-1 replication.

Emivirine (MKC-442) is a potent and selective nonnucleoside reverse transcriptase inhibitor for human immunodeficiency virus type 1.

GSK 224876 is a novel next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI). It has activity against efavirenz-resistant strains in the treatment of treatment-naive HIV-1-infected subjects.

AT-61 is a nonnucleoside analogue inhibitor of hepatitis B virus (HBV) replication.

CP-94707 is a new inhibitor of nonnucleoside reverse transcriptase (NNRTI).

U 95133 is a potent, broad-spectrum nonnucleoside reverse transcriptase inhibitor of drug-resistant isolates of human immunodeficiency virus type 1.

(+)-Dihydrocalanolide A (DHCal A; NSC 678323), an orally active non-nucleoside reverse transcriptase inhibitor, is used in HIV infection research.

PYR01 is a potent nonnucleoside reverse transcriptase inhibitor of HIV-1 and concurrently acts as a targeted activator to eliminate cells expressing HIV-1 [1].

NSAH (2-hydroxy-N'-[(E)-(2-hydroxynaphthalen-1-yl)methylidene]benzohydrazide) is a nonnucleoside inhibitor of human ribonucleotide reductase (hRR).with cell-free IC50 of 32 μM and cell-based IC50 of ~250 nM, respectively.

VCH-916 is a new nonnucleoside inhibitor of HCV NS5B polymerase.

VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.